Dr Hubert H. Fernandez discusses how the newly approved D1/D5 agonist Juvmo (tavapadon) fits into current treatment paradigms for adult Parkinson disease. empr.com/news/juvmo-tavapado…
Trial results will form the basis for a regulatory submission to use Elrexfio treatment earlier in relapsed or refractory multiple myeloma therapy. empr.com/news/elranatamab-pf…
Topline phase 3 data show tradipitant significantly reduced GLP-1–associated vomiting and severe nausea in overweight or obese adults. empr.com/news/tradipitant-ph…
Florida’s Hillsborough County remains a dengue hot spot and cooler weather may offer only a short break. #DengueOutbreak empr.com/news/florida-dengue…
The FDA approved the PARP inhibitor talazoparib with enzalutamide for adults with HRR gene-mutated metastatic castration-sensitive prostate cancer. #DrugApprovals empr.com/news/fda-approves-t…
There was fast uptake for Wegovy pill prescriptions after launch, meanwhile the rates for injectable weight management prescriptions did not slow down. empr.com/news/early-uptake-w…
With this approval, patients with CD may now initiate Skyrizi subcutaneously via an on-body injector induction pack or receive it as an intravenous infusion. empr.com/news/fda-approves-s…
The newly approved Zilbrysq autoinjector provides an alternative to the prefilled syringe for daily self-administration. empr.com/news/fda-approves-z…
MPR spoke with the global lead Juvmo investigator, Hubert H. Fernandez, MD, who talks about the key takeaways for clinicians considering the newly approved Parkinson disease Tx. empr.com/news/juvmo-tavapado…
Michelle Min, MD, MS, who presented at the Fall Clinical Dermatology Conference, met with the MPR team to discuss multidisciplinary collaboration in the treatment of cutaneous lupus. empr.com/reports/video-curre…
A new liquid formulation of cevimeline HCl offers a bioequivalent alternative for adult patients experiencing dry mouth tied to Sjögren disease. empr.com/news/evoxac-oral-so…
The FDA has approved Hibsago as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure. empr.com/news/fda-approves-h…
The FDA has approved the first generic equivalent of Climara Pro, offering a once-weekly transdermal option for managing moderate to severe vasomotor symptoms. empr.com/news/fda-approves-f…
Jemperli granted accelerated approval for stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. empr.com/news/fda-approves-d…
A potential vaccine that could prevent Alzheimer disease has been Fast Tracked by the FDA. A phase 1 trial showed promising, inducing antibodies to target the correct protofibrils and fibrils. empr.com/news/fda-fast-track…
Ryzumvi approval expanded to incorporate presbyopia. empr.com/news/ryzumvi-fda-ap…
📣 MPR Pod out now!
🔹 Once-monthly sub. long-acting formulation of olanzapine for schizophrenia;
👁️ Hovilpri for mucocutaneous HSV;
🔸 Tecentriq expanded;
🔹 Enspryng for thyroid eye disease; and
😰 Vanda’s Tx for Social Anxiety Disorder misses endpoint.
empr.com/news/mpr-weekly-dos…
Vanda Pharmaceuticals has paused the clinical program for VQW-765 after a phase 3 trial evaluating the drug for social anxiety disorder failed to show significant distress reduction compared with placebo. empr.com/news/phase-3-trial-…
Tecentriq and Tecentriq Hybreza approved in combination with a fluoropyrimidine and oxaliplatin, for the adjuvant treatment of stage III mismatch repair-deficient colon cancer. empr.com/news/fda-approves-a…
Weltruza approved as the first once-monthly long-acting injectable treatment for schizophrenia; a controlled steady release of olanzapine with no loading doses, no oral supplementation and no post-injection monitoring required. empr.com/news/once-monthly-w…
